UNLABELLED: WHAT'S KNOWN ON THE SUBJECT? AND WHAT DOES THE STUDY ADD?: Even after a negative set of prostate biopsies, the risk of undetected prostate cancer remains clinically significant. Predictive markers of such a risk are undefined. In addition to PSA and PSAD, low prostate volume and %fPSA are interesting time-varying risk factors and are relevant in biopsy decision-making. OBJECTIVE: To assess prospectively the time-varying risk of rebiopsy and of prostate cancer (PCa) detection after an initial negative biopsy protocol. PATIENTS AND METHODS: Over a period of 10 years, 1995 consecutive patients with initially negative biopsies were followed. Rebiopsies were performed in patients who had a persistent suspicion of PCa. Predictive factors for rebiopsy and for PCa detection were tested using univariate, multivariate and time-dependent models. RESULTS: A total of 617 men (31%) underwent at least one rebiopsy after a mean follow-up of 19 months. PCa detection rates during second, third, and fourth sets of biopsies were 16.7, 16.9 and 12.5%, respectively. The overall rate of detected PCa was 7.0%. The 5-year rebiopsy-free and PCa-free survival rates were 65.9 and 92.5%, respectively. Indications for rebiopsy were more frequently reported in patients having a high prostate-specific antigen (PSA) level (P = 0.006) or a high PSA density (PSAD; P < 0.001) and in younger patients (P = 0.008). The risk of PCa on rebiopsies was not correlated with age, but significantly increased more than twofold in cases of PSA >6 ng/mL, PSAD >0.15 ng/mL/g, free-to-total PSA ratio (%fPSA) <15, and/or prostate volume <50 mL. Time-dependent analyses were in line with these findings. The main study limitation was the lack of control of the absence of PCa and PSA kinetics in men not rebiopsied. CONCLUSIONS: The overall risk of detected PCa after an initial negative biopsy was low. In addition to PSA and PSAD, which are well-used in rebiopsy indications, low prostate volume and %fPSA are interesting time-varying risk factors for PCa on rebiopsy and could be relevant in biopsy decision-making.
UNLABELLED: WHAT'S KNOWN ON THE SUBJECT? AND WHAT DOES THE STUDY ADD?: Even after a negative set of prostate biopsies, the risk of undetected prostate cancer remains clinically significant. Predictive markers of such a risk are undefined. In addition to PSA and PSAD, low prostate volume and %fPSA are interesting time-varying risk factors and are relevant in biopsy decision-making. OBJECTIVE: To assess prospectively the time-varying risk of rebiopsy and of prostate cancer (PCa) detection after an initial negative biopsy protocol. PATIENTS AND METHODS: Over a period of 10 years, 1995 consecutive patients with initially negative biopsies were followed. Rebiopsies were performed in patients who had a persistent suspicion of PCa. Predictive factors for rebiopsy and for PCa detection were tested using univariate, multivariate and time-dependent models. RESULTS: A total of 617 men (31%) underwent at least one rebiopsy after a mean follow-up of 19 months. PCa detection rates during second, third, and fourth sets of biopsies were 16.7, 16.9 and 12.5%, respectively. The overall rate of detected PCa was 7.0%. The 5-year rebiopsy-free and PCa-free survival rates were 65.9 and 92.5%, respectively. Indications for rebiopsy were more frequently reported in patients having a high prostate-specific antigen (PSA) level (P = 0.006) or a high PSA density (PSAD; P < 0.001) and in younger patients (P = 0.008). The risk of PCa on rebiopsies was not correlated with age, but significantly increased more than twofold in cases of PSA >6 ng/mL, PSAD >0.15 ng/mL/g, free-to-total PSA ratio (%fPSA) <15, and/or prostate volume <50 mL. Time-dependent analyses were in line with these findings. The main study limitation was the lack of control of the absence of PCa and PSA kinetics in men not rebiopsied. CONCLUSIONS: The overall risk of detected PCa after an initial negative biopsy was low. In addition to PSA and PSAD, which are well-used in rebiopsy indications, low prostate volume and %fPSA are interesting time-varying risk factors for PCa on rebiopsy and could be relevant in biopsy decision-making.
Authors: Mark W Ball; Ashley E Ross; Kamyar Ghabili; Chunwoo Kim; Changhan Jun; Doru Petrisor; Li Pan; Jonathan I Epstein; Katarzyna J Macura; Dan S Stoianovici; Mohamad E Allaf Journal: Urology Date: 2017-07-19 Impact factor: 2.649
Authors: William A Sterling; Joseph Weiner; David Schreiber; Komal Mehta; Jeffrey P Weiss Journal: Int Urol Nephrol Date: 2016-08-31 Impact factor: 2.370
Authors: Raju Chelluri; Amichai Kilchevsky; Arvin K George; Abhinav Sidana; Thomas P Frye; Daniel Su; Michele Fascelli; Richard Ho; Steven F Abboud; Baris Turkbey; Maria J Merino; Peter L Choyke; Bradford J Wood; Peter A Pinto Journal: J Urol Date: 2016-02-13 Impact factor: 7.450
Authors: Jeannette Kratzenberg; Georg Salomon; Pierre Tennstedt; Paolo Dell'Oglio; Derya Tilki; Axel Haferkamp; Markus Graefen; Katharina Boehm Journal: World J Urol Date: 2018-01-13 Impact factor: 4.226
Authors: Ho Won Kang; Jin Bak Yang; Whi-An Kwon; Young-Suk Lee; Won Tae Kim; Yong-June Kim; Seok-Joong Yun; Sang-Cheol Lee; Isaac Yi Kim; Wun-Jae Kim Journal: J Korean Med Sci Date: 2013-11-26 Impact factor: 2.153
Authors: Masakatsu Oishi; Toshitaka Shin; Chisato Ohe; Nima Nassiri; Suzanne L Palmer; Manju Aron; Akbar N Ashrafi; Giovanni E Cacciamani; Frank Chen; Vinay Duddalwar; Mariana C Stern; Osamu Ukimura; Inderbir S Gill; Andre Luis de Castro Abreu Journal: J Urol Date: 2019-02 Impact factor: 7.600